NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital
Plans to Investigate All Records to Ensure Board Did Not Breach Fiduciary Duty
DALLAS, July 11, 2023 /PRNewswire/ -- NexPoint Event Driven Fund today issued a demand letter to the Board of Directors of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) (the "Company") to make available all books and records surrounding the proposed acquisition of the Company in order to investigate whether any board members breached their fiduciary duties in connection with the proposed acquisition. NexPoint Event Driven Fund is advised by NexPoint Asset Management, L.P. and together with other stockholders (collectively, "NexPoint"), are members of a group who beneficially own approximately 11.7% of the Company's outstanding common stock.
The full demand letter can be found here.
About NexPoint Event Driven Fund
NexPoint Event Driven Fund is an open-end mutual fund advised by NexPoint Asset Management, L.P. The fund invests in event catalysts including mergers, acquisitions, tender offers, restructuring, spin-offs, refinancings, recapitalizations or economic events that can impact specific industries.
About NexPoint Asset Management, L.P.
NexPoint Asset Management, L.P. is an SEC-registered investment adviser. NexPoint Asset Management, L.P. is the adviser to a suite of registered funds, including open-end mutual funds, closed-end funds, and an exchange-traded fund. The funds draw on NexPoint's investment capabilities, covering a range of asset classes and strategies. For more information visit www.nexpointassetmgmt.com/.
CONTACT
Mike Geller
Prosek Partners for NexPoint
mgeller@prosek.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nexpoint-sends-demand-letter-for-books-and-records-to-paratek-pharmaceuticals-in-connection-with-proposed-acquisition-by-gurnet-point-capital-301874809.html
SOURCE NexPoint Asset Management, L.P.
Ausgewählte Hebelprodukte auf Paratek Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Paratek Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Paratek Pharmaceuticals Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Paratek Pharmaceuticals Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Paratek Pharmaceuticals nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 02.01.19 | Paratek Pharmaceuticals Buy | Canaccord Adams | |
| 23.11.18 | Paratek Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 18.07.17 | Paratek Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 11.04.17 | Paratek Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 04.04.17 | Paratek Pharmaceuticals Outperform | Wedbush Morgan Securities Inc. |